Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 2 of 2

Publication Record


Predicting Severe Pneumonia Outcomes in Children.
Williams DJ, Zhu Y, Grijalva CG, Self WH, Harrell FE, Reed C, Stockmann C, Arnold SR, Ampofo KK, Anderson EJ, Bramley AM, Wunderink RG, McCullers JA, Pavia AT, Jain S, Edwards KM
(2016) Pediatrics 138:
MeSH Terms: Age Factors, Child, Preschool, Community-Acquired Infections, Female, Hospitalization, Humans, Infant, Intensive Care Units, Pediatric, Length of Stay, Lung, Male, Models, Statistical, Patient Admission, Patient Outcome Assessment, Pneumonia, Prognosis, Prospective Studies, Respiration, Artificial, Risk Assessment, Severity of Illness Index, Shock, United States, Vital Signs
Show Abstract · Added July 27, 2018
BACKGROUND - Substantial morbidity and excessive care variation are seen with pediatric pneumonia. Accurate risk-stratification tools to guide clinical decision-making are needed.
METHODS - We developed risk models to predict severe pneumonia outcomes in children (<18 years) by using data from the Etiology of Pneumonia in the Community Study, a prospective study of community-acquired pneumonia hospitalizations conducted in 3 US cities from January 2010 to June 2012. In-hospital outcomes were organized into an ordinal severity scale encompassing severe (mechanical ventilation, shock, or death), moderate (intensive care admission only), and mild (non-intensive care hospitalization) outcomes. Twenty predictors, including patient, laboratory, and radiographic characteristics at presentation, were evaluated in 3 models: a full model included all 20 predictors, a reduced model included 10 predictors based on expert consensus, and an electronic health record (EHR) model included 9 predictors typically available as structured data within comprehensive EHRs. Ordinal regression was used for model development. Predictive accuracy was estimated by using discrimination (concordance index).
RESULTS - Among the 2319 included children, 21% had a moderate or severe outcome (14% moderate, 7% severe). Each of the models accurately identified risk for moderate or severe pneumonia (concordance index across models 0.78-0.81). Age, vital signs, chest indrawing, and radiologic infiltrate pattern were the strongest predictors of severity. The reduced and EHR models retained most of the strongest predictors and performed as well as the full model.
CONCLUSIONS - We created 3 risk models that accurately estimate risk for severe pneumonia in children. Their use holds the potential to improve care and outcomes.
Copyright © 2016 by the American Academy of Pediatrics.
0 Communities
1 Members
0 Resources
MeSH Terms
Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial.
Newhouse P, Kellar K, Aisen P, White H, Wesnes K, Coderre E, Pfaff A, Wilkins H, Howard D, Levin ED
(2012) Neurology 78: 91-101
MeSH Terms: Administration, Cutaneous, Aged, Aged, 80 and over, Attention, Body Weight, Cognitive Dysfunction, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Mental Recall, Neuropsychological Tests, Nicotine, Nicotinic Agonists, Pilot Projects, Psychiatric Status Rating Scales, Reaction Time, Vital Signs
Show Abstract · Added March 3, 2020
OBJECTIVE - To preliminarily assess the safety and efficacy of transdermal nicotine therapy on cognitive performance and clinical status in subjects with mild cognitive impairment (MCI).
METHODS - Nonsmoking subjects with amnestic MCI were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months. Primary outcome variables were attentional improvement assessed with Connors Continuous Performance Test (CPT), clinical improvement as measured by clinical global impression, and safety measures. Secondary measures included computerized cognitive testing and patient and observer ratings.
RESULTS - Of 74 subjects enrolled, 39 were randomized to nicotine and 35 to placebo. 67 subjects completed (34 nicotine, 33 placebo). The primary cognitive outcome measure (CPT) showed a significant nicotine-induced improvement. There was no statistically significant effect on clinician-rated global improvement. The secondary outcome measures showed significant nicotine-associated improvements in attention, memory, and psychomotor speed, and improvements were seen in patient/informant ratings of cognitive impairment. Safety and tolerability for transdermal nicotine were excellent.
CONCLUSION - This study demonstrated that transdermal nicotine can be safely administered to nonsmoking subjects with MCI over 6 months with improvement in primary and secondary cognitive measures of attention, memory, and mental processing, but not in ratings of clinician-rated global impression. We conclude that this initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.
CLASSIFICATION OF EVIDENCE - This study provides Class I evidence that 6 months of transdermal nicotine (15 mg/day) improves cognitive test performance, but not clinical global impression of change, in nonsmoking subjects with amnestic MCI.
0 Communities
1 Members
0 Resources
MeSH Terms